These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


406 related items for PubMed ID: 23444197

  • 41. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V, Cannon JR, Greenamyre JT.
    J Neurosci Res; 2010 Feb 01; 88(2):420-7. PubMed ID: 19681169
    [Abstract] [Full Text] [Related]

  • 42. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y, Kordower JH.
    Neurobiol Dis; 2007 Jan 01; 25(1):134-49. PubMed ID: 17055279
    [Abstract] [Full Text] [Related]

  • 43. Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.
    Sharma N, Nehru B.
    Inflammopharmacology; 2018 Apr 01; 26(2):349-360. PubMed ID: 29027056
    [Abstract] [Full Text] [Related]

  • 44. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H, Wu YC, Nakamura M, Liang Y, Tanaka Y, Holmes S, Dawson VL, Dawson TM, Ross CA, Smith WW.
    Neurobiol Aging; 2007 Nov 01; 28(11):1709-17. PubMed ID: 16978743
    [Abstract] [Full Text] [Related]

  • 45. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.
    Sharma SK, Ebadi M.
    Antioxid Redox Signal; 2003 Jun 01; 5(3):251-64. PubMed ID: 12880480
    [Abstract] [Full Text] [Related]

  • 46. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S, Fukushima S, Sato H, Sasaki A, Koga K, Koyama S, Kato T.
    PLoS One; 2014 Jun 01; 9(2):e89076. PubMed ID: 24586512
    [Abstract] [Full Text] [Related]

  • 47. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW, Brundin P.
    Mov Disord; 2013 Jan 01; 28(1):31-40. PubMed ID: 23390095
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Viral vectors, animal models and new therapies for Parkinson's disease.
    Schneider B, Zufferey R, Aebischer P.
    Parkinsonism Relat Disord; 2008 Jan 01; 14 Suppl 2():S169-71. PubMed ID: 18585946
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
    Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J.
    FASEB J; 2005 Apr 01; 19(6):533-42. PubMed ID: 15791003
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
    Bassil F, Guerin PA, Dutheil N, Li Q, Klugmann M, Meissner WG, Bezard E, Fernagut PO.
    Mov Disord; 2017 Aug 01; 32(8):1230-1239. PubMed ID: 28556404
    [Abstract] [Full Text] [Related]

  • 59. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
    Yamakawa K, Izumi Y, Takeuchi H, Yamamoto N, Kume T, Akaike A, Takahashi R, Shimohama S, Sawada H.
    Biochem Biophys Res Commun; 2010 Jan 01; 391(1):129-34. PubMed ID: 19900407
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 21.